Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CPX-351 for Older Patients with AML

January 11th 2017

Risk-directed Approaches to AML Therapy

January 11th 2017

T-Cell Lymphoma Options Burgeoning With Ongoing Clinical Trials

January 7th 2017

Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin to improve outcomes for these patients.

MDS: Before and After Stem Cell Transplantation

January 6th 2017

Transplantation Candidacy in MDS

January 6th 2017

Emerging Therapies in Low-Risk MDS

January 6th 2017

Hypomethylating Agents in Low-Risk MDS

January 6th 2017

Sequencing Strategies in Low-Risk MDS

January 6th 2017

Considering Lenalidomide in Non-Del 5q MDS

January 6th 2017

Patient Selection Considerations With Iron Chelation Therapy in MDS

January 6th 2017

Evidence With Iron Chelation Therapy in MDS

January 6th 2017

Monitoring for Iron Overload in Transfusion-Dependent MDS

January 6th 2017

Quality of Life in Transfusion-Dependent MDS

January 6th 2017

MDS: When the Prognostic Models Fall Short

January 6th 2017

Accurate Risk Assessment in MDS

January 6th 2017

Understanding the Recent WHO MDS Classification Updates

January 6th 2017

Novel Therapies Likely to Transform AML Landscape

January 4th 2017

A combination regimen of the BCL-2 inhibitor venetoclax plus low-dose cytarabine demonstrated an acceptable safety and pharmacokinetic profile in elderly patients with treatment-naïve acute myeloid leukemia.

Expert Explains WHO Classification Refinements in Hematologic Malignancies

December 30th 2016

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Give Precision Medicine a Chance

December 28th 2016

Negative reports evaluating molecularly selected agents should not derail the process of developing future therapies by employing a precision medicine approach.